Applied DNA Sciences, Inc. (APDN)
| Market Cap | 883.02K |
| Revenue (ttm) | 3.74M |
| Net Income (ttm) | -23.59M |
| Shares Out | 1.10M |
| EPS (ttm) | -101.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 642,088 |
| Open | 0.8000 |
| Previous Close | 0.8469 |
| Day's Range | 0.7900 - 0.8210 |
| 52-Week Range | 0.7800 - 380.0000 |
| Beta | 0.84 |
| Analysts | Strong Buy |
| Price Target | 75.00 (+9,275.0%) |
| Earnings Date | May 9, 2025 |
About APDN
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-base... [Read more]
Financial Performance
In 2024, Applied DNA Sciences's revenue was $3.43 million, a decrease of -74.33% compared to the previous year's $13.37 million. Losses were -$7.23 million, -27.36% less than in 2023.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for APDN stock is "Strong Buy" and the 12-month stock price forecast is $75.0.
News
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
STONY BROOK, NY / ACCESS Newswire / April 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on April 7, 2025, it received a...
Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement
- Company Revamps Pharmacogenomics Go-To-Market Strategy, Targets Validated PGx Assay Towards Specific Use Cases - STONY BROOK, NY / ACCESS Newswire / April 1, 2025 / Applied DNA Sciences, Inc. (NASDA...
Applied DNA Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A Laboratory-Developed Test
STONY BROOK, NY / ACCESS Newswire / March 26, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA C...
Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025
STONY BROOK, NY / ACCESS Newswire / March 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effec...
Applied DNA Sciences, Inc. (APDN) Q1 2025 Earnings Call Transcript
Applied DNA Sciences, Inc. (NASDAQ:APDN) Q1 2025 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sanjay Hurry - Executive Director, IR & Corporate Communications Beth Jantz...
Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress
- Announces Exit of DNA Tagging and Security Products and Services Business Segment - - Workforce Reduction of 20% of Headcount Implemented in January - - GMP Site 1 Facility Complete and Certified fo...
Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025
Investor Call and Webcast Scheduled for 4:30 P.M ET STONY BROOK, NY / ACCESS Newswire / February 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polym...
Applied DNA Reminds Shareholders to Vote Ahead of Special Meeting on February 14
STONY BROOK, NY / ACCESS Newswire / February 11, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today issued a reminder to it...
Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates
- Signals Start of New Commercialization Phase for LineaRx Subsidiary - - Company Negotiating GMP Supply Agreement - - Company Reaffirms Strategic Restructuring Timeline - STONY BROOK, NY / ACCESSWIRE...
Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter
STONY BROOK, NY / ACCESSWIRE / January 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announ...
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA
- Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies - STONY BROOK, NY / ACCESSWIRE / December 18, 2024 / Applied DNA Sci...
Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines
- Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership - - Build-out of GMP Manufacturing Facility to be Completed by January 9, 2025 - - Webcast and Conference Call ...
Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out
STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today anno...
Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement
STONY BROOK, NY / ACCESSWIRE / October 30, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the pricing of a re...
Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16
STONY BROOK, NY / ACCESSWIRE / October 15, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA"), a leader in PCR-based DNA technologies, today announced that Dr. James A. Hayward, president...
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit
- Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing - STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APD...
Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application
- Recurring and Accelerated Receipt of Order Reflects Customer Commitment to Linea DNA - STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or ...
Applied DNA Launches Mpox Clade I and Clade II Testing Service
STONY BROOK, NY / ACCESSWIRE / September 11, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that its wholly-owned clinical labor...
Applied DNA Selected by LRQA for Isotopic Testing Pilot Project in Pakistan
- Pilot Project To Demonstrate Effectiveness of CertainT® for Cotton Textile Traceability - STONY BROOK, NY / ACCESSWIRE / September 4, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a...
Why Is Diagnostic Tests Provider Applied DNA Sciences Stock Trading Higher On Friday?
Applied DNA Sciences, Inc. APDN stock traded higher on Friday on a strong session volume of 114.23 million, compared to the average volume of 6.78 million, according to data from Benzinga Pro.
Applied DNA Submits Validation Package to New York State Department of Health to Expand Linea Mpox Virus 1.0 Assay to Mpox Clade I
-Validation Studies Confirmed the Assay Can Detect Mpox Clade I and Clade Ib in addition to Clade II- STONY BROOK, NY / ACCESSWIRE / August 23, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Co...
Applied DNA To Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I
STONY BROOK, NY / ACCESSWIRE / August 19, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its intention to seek an expansion of t...
Applied DNA Sciences, Inc. (APDN) Q3 2024 Earnings Call Transcript
Applied DNA Sciences, Inc. (NASDAQ:APDN) Q3 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Corporate Participants Sanjay Hurry - Head of IR Beth Jantzen - Chief Financial Officer Jim Hayward...
Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results
- Conference Call/Webcast Scheduled for Today at 4:30 PM ET - STONY BROOK, NY / ACCESSWIRE / August 8, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR...
Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024
STONY BROOK, NY / ACCESSWIRE / August 7, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announc...